[Isobaric and hyperbaric bupivacaine 0.5% solution for spinal anesthesia]

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Spinal anesthesia is a common technique for lower limb and abdominal surgeries.
• Bupivacaine is a widely used local anesthetic for spinal anesthesia.
• The physical properties of bupivacaine solutions (isobaric vs. hyperbaric) can influence anesthetic spread and effects.

Purpose of the Study:

• To compare the efficacy and safety of 0.5% isobaric bupivacaine versus 0.5% hyperbaric bupivacaine (at different doses) for spinal anesthesia.
• To evaluate the onset, duration, and level of sensory and motor blockade.
• To assess the hemodynamic effects, specifically blood pressure changes and the need for vasopressors.

Main Methods:

• A study involving 45 patients undergoing lower limb or lower abdominal surgery.
• Patients were divided into three groups receiving different spinal anesthesia regimens: 3 ml of 0.5% isobaric bupivacaine, or 3 ml or 2 ml of 0.5% hyperbaric bupivacaine.
• Data collected included blood pressure, segmental level of analgesia, time to motor blockade, and duration of analgesia and motor blockade.

Main Results:

• All groups achieved complete motor blockade; however, Group 2 (3 ml hyperbaric) experienced significant hypotension requiring vasopressors in 70% of cases.
• The average segmental level of analgesia varied: T9 for isobaric, C8 for hyperbaric (3 ml), and T4 for hyperbaric (2 ml).
• Adequate surgical anesthesia was achieved with 3 ml of isobaric bupivacaine and 2 ml of hyperbaric bupivacaine, with the latter showing a faster onset of motor blockade.

Conclusions:

• Both 3 ml of 0.5% isobaric bupivacaine and 2 ml of 0.5% hyperbaric bupivacaine are effective for surgical anesthesia in the studied procedures.
• The 2 ml dose of hyperbaric bupivacaine offers a favorable balance of efficacy and reduced hemodynamic compromise compared to the 3 ml dose.
• Careful dose selection is crucial when using hyperbaric bupivacaine to optimize anesthetic effects and minimize adverse events.